Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphangioleiomyomatosis × Celecoxib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 7 Breast Neoplasms 6 Head and Neck Neoplasms 4 Adenomatous Polyposis Coli 4 Sarcoma 3 Glioblastoma 3 Colonic Neoplasms 3 Central Nervous System Neoplasms 3 Rectal Neoplasms 2 Paranasal Sinus Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Laryngeal Neoplasms 2 Gliosarcoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Carcinoma In Situ 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Tobacco Use Disorder 1 Stomatitis 1 Smoldering Multiple Myeloma 1 Smoking 1 Recurrence 1 Prostatic Neoplasms 1 Prostatic Hyperplasia 1 Precancerous Conditions 1 Pharyngeal Neoplasms 1 Peritoneal Neoplasms 1 Papilloma 1 Pancreatic Neoplasms 1

Interventions

Sirolimus 5 Everolimus 3 carbon-11 acetate 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02484664 2022-01-20

COLA

Brigham and Women's Hospital

Phase 2 Completed

12 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡